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Abstract
Background: Loss of heterozygosity of chromosome 10q26 has been shown to be associated with
the aggressiveness of astrocytic tumors (or astrocytomas), but the responsible gene(s) residing in
this region has not been fully identified. The BCCIP gene is located at chromosome 10q26. It
encodes a BRCA2 and CDKN1A (p21) interacting protein. Previous studies have shown that
down-regulation of BCCIP impairs recombinational DNA repair, G1/S cell cycle checkpoint, p53
trans-activation activity, cytokinesis, and chromosome stability, suggesting a potential role of BCCIP
in cancer etiology. In this study, we investigated whether BCCIP is altered in astrocytomas.
Methods: Genomic DNA from 45 cases of grade IV astrocytic tumor (glioblastoma) tissues and
12 cases of normal tissues were analyzed by quantitative PCR. The BCCIP protein expression in 96
cases of grade II–IV astrocytic tumors was detected by immunohistochemistry (IHC). IHC staining
of glial fibrillary acid protein (GFAP), a marker for astrocytic cells, was used to identify cells of the
astrocytic lineage.
Results: We found that BCCIP protein is expressed in normal cells with positive staining of GFAP.
However, BCCIP protein expression was not detectable in ~45% of all astrocytic tumors, and in >
60% in the grade IV glioblastoma. About 45% glioblastoma have significant (p < 0.01) reduction of
BCCIP gene copy number when compared to normal DNA. Furthermore, the frequency of lacking
BCCIP expression is associated with the aggressiveness of astrocytic tumors.
Conclusion: Our data implicate a role of BCCIP in astrocytic tumorigenesis, and lack of BCCIP may
be used as a marker for astrocytomas.
Background
Astrocytic tumor, or astrocytoma, is one of the most lethal
forms of brain cancer although they rarely metastasize.
Improvement of astrocytoma interventions requires fur-
ther understanding on the genetic alterations associated
with these tumors. Loss of heterozygosity (LOH) of chro-
Published: 4 August 2009
BMC Cancer 2009, 9:268 doi:10.1186/1471-2407-9-268
Received: 29 October 2008
Accepted: 4 August 2009
This article is available from: http://www.biomedcentral.com/1471-2407/9/268
© 2009 Liu et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
Page 2 of 8
(page number not for citation purposes)
mosome 10q (especially region 10q25.3–26.2) is fre-
quently associated with astrocytoma [1-11]. LOH on
chromosome 10q26 is highly correlated with a poor prog-
nosis for astrocytoma [1-7,9-12], and perhaps is the one
of the most reliable prognosis markers associated with a
worse outcome [8,9,13]. Thus, identifying the gene(s) in
this region associated with this form of brain tumor is of
critical importance for astrocytoma intervention. In addi-
tion to brain tumor, LOH of 10q26 has been shown to be
associated with prostate cancers, endometrial cancers, and
lung cancers [14-17], further suggesting the importance of
identifying the tumor related gene(s) on 10q26.
Genomic instability is a major driving force for tumor
progression. The BRCA2 gene plays critical roles in the
maintenance of genomic stability by regulating homolo-
gous recombination, and BRCA2  defects are associated
with predisposition to various human cancer. Although
mutation of BRCA2 itself is involved in only a small pop-
ulation of human cancer, the germline BRCA2 mutations
are highly penetrative to cancer. This suggests that the
entire molecular pathway of BRCA2 are critical for cancer
prevention, and other proteins related to BRCA2 may con-
tribute to additional tumors [18]. Thus identifications and
analyses of novel BRCA2 interacting protein may provide
unique opportunities to identify additional genetic factors
involved in tumorigenesis. We and others have previously
reported BCCIP as a BRCA2 and CDKN1A [19] interacting
protein [20-23]. We have shown that the chromatin
bound fraction of BCCIP co-localizes with BRCA2 and
contributes to BRCA2 and RAD51 nuclear focus forma-
tion [22]. A ~50% down-regulation of BCCIP is sufficient
to inhibit homologous recombination, and both the
BRCA2 and p21 interaction domains of BCCIP play a role
in regulating homologous recombination [22,24,25]. Fur-
thermore, BCCIP has been shown to play a role in sup-
porting p53 transcription activity, and the completion of
cytokinesis during mitosis [26,27]. All these support a crit-
ical role of BCCIP in the maintenance of genomic stabil-
ity.
The human BCCIP gene is located at 10q26.1 [20], and a
recent report suggested that BCCIP may be absent in at
least one astrocytoma cell line [28]. We previously
showed that the A172 astrocytic brain tumor cell line has
reduced expression of BCCIPα [20]. Given that BCCIP is
involved in important processes relevant to the mainte-
nance of genome stability and its localization at 10q26,
we investigated the possibility of BCCIP alterations in
more than 100 cases of astrocytomas. Because brain
tumor in the astrocyte lineage are the most common type
[29,30], we emphasized our analyses on the astrocytic
tumors including the grade IV glioblastoma multiforme.
We found that BCCIP is down-regulated in a major por-
tion of these brain tumors. Furthermore, BCCIP down-
regulation is correlated with the aggressiveness of astrocy-
tomas. These data suggest BCCIP alteration as a new
marker for astrocytomas.
Methods
Quantitative Real-Time PCR detection of BCCIP copy 
number
A total of 45 cases of anonymous genomic DNA were iso-
lated from grade IV astrocytoma as previously reported
[5,31]. Twelve cases of DNA from peripheral blood leuko-
cytes were used as control for normal BCCIP gene dosage
determination. Real-time PCR was done using the SYBR
Green strategy with a DNA Engine Opticon™ 2 Real-Time
Detection System (M J Research Inc. South San Francisco,
CA). Each pair of primers was optimized to amplify only
the anticipated PCR products, which were verified by
DNA sequencing and melting curve analysis. The primers
for BCCIP are as follows: exon 5: 5'-TGC TTT CTA GGG
TAC CCA GTG-3' (forward) and 5'-CCA CAG GCT TGG
TGG TGT C-3'(reverse, 129 bp); exon 6: 5'-GGC ACA CAG
AAC CAA TAA GCC-3' (forward) and 5'-CAT TTG CAA
ACA TTA ACG CAG C-3' (reverse, 136 bp); exon 7: 5'-TCA
ACT ACT CAG TGC AGG AGG AG-3' (forward) and 5'-
CAG TTT ATC CAT GAT TTC GTT CAT C-3' (reverse, 135
bp); exon 9: 5'-AAG TGA CAG CCC TGG TTT CTC-3' (for-
ward) and 5'-ATG AGC CTC CTA AAT CCC TGA C-3'
(reverse, 130 bp). To normalize the copy number of
BCCIP gene, the copy number of glyseraldehyde-3-phos-
phate dehydrogenase (GAPDH) was used as an internal
control. The primers for GAPDH are: 5'-AAC GTG TCA
GTG GTG GAC CTG-3' (forward) and 5'-AGT GGG TGT
CGC TGT TGA AGT-3' (reverse, 160 bp), as validated and
described previously [5,32]. This pair of primers amplifies
a single band as confirmed by melting curve analysis with
the DNA Engine Opticon™ 2 Real-Time Detection System
(M J Research Inc. South San Francisco, CA), and con-
firmed to be the coding gene of GAPDH by DNA sequenc-
ing. To our knowledge, this pair of primer does not amply
GAPDH pseudogenes. In each PCR analyses, we used 25
μl of reaction volume containing 4 μl of DNA, 100 μM
each of the primers, and 12.5 μl of 2× master mix from
DyNAmo HS SYBR Green qPCR kit (Finnzymes). Stand-
ard curve to calibrate DNA concentration was performed
for all amplifications for each pair of primers. The PCR
reaction tubes were first incubated for 15 minutes at
95°C, followed by 40 cycles of 30 seconds at 95°C, 20
seconds at optimized annealing temperature depending
on the primers, and 20 seconds at 72°C.
Antibodies and Immunohistochemistry of BCCIP and GFAP 
in brain tumors
Rabbit anti-BCCIPα/β antibodies were reported previ-
ously [20]. Paraffin embedded brain tumor tissue array
slides (Catalog No GL801, BS17001, and BS17014) were
purchased from US Biomax (Rockvile, MD). The coreBMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
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diameter is 1.5 mm, and the slides have thickness of 5 μm.
The pathological grade of tumor on the array were pro-
vided by the slide supplier, and later confirmed by us
when the slides were evaluated. The astrocytoma grade II–
IV in pathology diagnosis is equivalent to low-grade mod-
erately-differentiated astrocytoma, anaplastic astrocy-
toma, and undifferentiated glioblastoma multiforme
respectively. These slides originally contain more than
100 cases of independent astrocytoma, 12 cases of oli-
godendroglioma, and 5 cases of ependymomas. Some of
the cases were eliminated from data analysis due to lack of
tumor tissues on the cores of the particular cases. This was
caused by tissue detachment from the slides during the
staining process, or because the presence of tumor tissue
cannot be verified. Thus, a total 96 cases of astrocytomas,
6 cases of oligodendrogliomas, and 5 cases of ependymo-
mas are reported here. Because objective of this study is to
perform a retrospective determination on whether BCCIP
is altered in existing specimens without contacting with
living individual, no information on the patient identities
and clinical outcomes are available for the investigators,
approval for human subject research was deemed unnec-
essary.
The astrocytomas are in the astrocytic lineage, and the
astrocytic cells often express a unique marker glial fibril-
lary acid protein (GFAP). Based on staining of non-tumor
brain tissue, BCCIP is not uniformly expressed in brain
tissue, but its expression can be detected in GFAP positive
cells (see Results section). Therefore, we stained GFAP to
identify the astrocytic tumor cells in the sections. Double
staining of the same slide with GFAP and BCCIP turned
out to be challenging with the available antibodies. Thus,
two neighboring serial sections of these slides were
stained with anti-GFAP monoclonal antibody (Chemicon
International, Temecula, CA) and anti-BCCIP antibody
respectively using routine immunohistochemistry (IHC)
protocols. Briefly, slides were de-paraffinized with xylene
for 10 min, and repeated three times. The antigen was
retrieved in citrate acid buffer (pH6.5) by steaming in a
rice cooker for 20 min. Following antigen retrieval, the
endogenous peroxidase activity was blocked at room tem-
perature by 20 minutes of incubation with 1% H2O2 in
methanol. The slides were blocked with 5% milk in TBS-T
(25 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Tween20)
for 30 min at room temperature, and then incubated with
1:100 diluted affinity-purified rabbit polyclonal anti-
BCCIP antibodies for 3 hrs at room temperature. This
BCCIP antibody has been reported previously [20].
Following 3 times wash with TBS-T, the slides were incu-
bated for 1 hr at room temperature with anti-Rabbit IgG
secondary antibody (1:100) that was conjugated with
horseradish peroxidase. The chromogenic substrate
diaminobenzidine (DAB) was used as a chromogen to
stain BCCIP positive cells (brown color). Haematoxylin
was used as contrast staining for BCCIP negative cell
nuclei (blue color). After mounting, the slides were
observed under microscope. When the BCCIP nuclear
stain was found in less than 5% of tumor cells, the case
was scored as BCCIP negative. When more than 5% tumor
cells are stained BCCIP positive, the case was considered
BCCIP positive. For GFAP staining and evaluation, the
same as BCCIP was used, except anti-GFAP monoclonal
antibody was used as first antibody, and anti- mouse IgG
(1:100) was used as the secondary antibody which was
conjugated with horseradish peroxidase.
Results
Reduction of BCCIP gene dosage in brain tumors
The BCCIP gene is located at chromosome 10q26.2 [20],
a region frequently altered in brain tumors. The BCCIP
gene also functions in cell cycle control, homologous
recombination, mitosis, and is required to maintain the
transactivation activity of wild type p53 [19,22-24,26,27].
Therefore, we were interested in determining whether
altered BCCIP is associated with brain tumors. We first
estimated the BCCIP gene copy numbers in genomic DNA
from 45 cases of glioblastomas (grade IV). Due to the lim-
ited amount DNA available for this study, we used quan-
titative PCR to assess the BCCIP gene dosage. We
performed Real-Time PCR using four independent sets of
primers within exons 5, 6, 7, and 9 of BCCIP according to
the genomic structure reported previously [33]. First, the
relative level of BCCIP gene was determined from DNA of
lymphocytes (see Methods). This provides a spectrum of
BCCIP signals in normal tissues. The average of these sig-
nals from the normal DNA, and its standard deviation
were calculated. Based on the Gaussian (or normal) distri-
bution, the 99% confidence limit (p < 0.01) was set at
2.58 fold of the standard deviation, and the 95% confi-
dence limit (P < 0.05) was set at 1.96 fold of the standard
deviation. Then, the relative dosage of BCCIP gene in
tumor DNA was compared with the distribution of nor-
mal DNA. If the copy numbers of two independent BCCIP
exons are less than the 99% confidence line of the normal
DNA, a "BCCIP loss" was scored for this case of tumor. We
found that 20 out of 45 cases of glioblastoma DNA have
significant loss of BCCIP with p < 0.01, an overall rate of
44.5%. In addition, 14 cases (31.1%) have BCCIP loss
with 0.01 < p < 0.05. Thus a total of ~75% glioblastomas
have BCCIP loss (p < 0.05). It was worth-noting that five
cases of brain tumors (labeled as case A, B, C, D, and E in
Figure 1) have reduced copy numbers in some exons, but
higher copy numbers in other parts of the gene, indicating
that other types of alteration such as regional amplifica-
tion of the gene could have occurred in addition to dele-
tion. Southern blot analyses for these tumor DNAs were
impossible due to lack of sufficient DNA specimens. Nev-BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
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ertheless, our data indicate that BCCIP gene loss or altera-
tion is common in glioblastomas.
Loss of BCCIP protein expression in brain tumor
To confirm the loss of BCCIP, we measured the BCCIP
protein expression in brain tumor tissue sections. These
cases were not related to the cases presented in Figure 1,
but were obtained from an independent source (US
Biomax, Rockvile, MD) in the form of tissue arrays,
because no tissue slides were available for the same cases
as reported in Figure 1. The pathological grades of these
tumors were provided by the supplier of the tissue arrays,
but confirmed by experienced pathologist co-authors (HL
and HO) based on the sections. Because majority of the
tumor on the slides are astrocytoma, and most astrocytic
tumor cells express the unique marker glial fibrillary acid
protein (GFAP) [34,35], we first checked if BCCIP is
expressed in normal GFAP positive cells. Using serial sec-
tions to stain normal brain tissue with anti-GFAP and
anti-BCCIP antibodies (Figure 2, top panels), we found
that BCCIP protein is mainly expressed in GFAP positive
cells.
Then, we stained serial sections of the tumor tissue arrays
with anti-GFAP and anti-BCCIP antibodies. Because
BCCIP is mainly expressed in GFAP positive cells, we
grouped the tumors based on their GFAP status (Table 1).
As shown in Table 1, among 91 cases of GFAP positive
astrocytomas, 40 were BCCIP negative, an overall rate of
44.8%. Three of the five GFAP negative astrocytomas are
also BCCIP negative. It has been established that altera-
tion of 10q25.3–26.1 is associated with high grade and
poor prognosis of astrocytic tumors [7-9,36]. Interest-
ingly, we found that 5 out of 26 cases (19.2%) WHO
Copy numbers of BCCIP exons detected by quantitative Real-Time PCR Figure 1
Copy numbers of BCCIP exons detected by quantitative Real-Time PCR. The copy number of exons 5, 6, 7, and 9 
were measured in 10 cases of normal brain tissue DNA (diamond marker), and 45 cases of glioblastoma DNA (see Materials 
and Methods for details). The 95% and 99% confidence ranges of the copy number in normal tissues are marked. Many tumor 
DNAs showed reduction of BCCIP copy numbers. However, five cases of tumor DNA (marked as cases A-E) have reduced 
BCCIP copy numbers at some exons but increased in others. These re-arrangements likely cause inactivation of the BCCIP 
gene.BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
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grade II astrocytomas are BCCIP negative, whereas 13/29
(44.8%) WHO grade III and 25/41 (60.1%) WHO grade
IV astrocytomas are BCCIP negative (Figure 3). Based on
a Chi-square test, there is a statistically higher frequency of
BCCIP negativity in grade III (p < 0.05) and IV (p < 0.01)
tumors than that of the grade II tumors, but there was no
statistic difference between grades III and IV (p > 0.05).
The correlation of lacking BCCIP expression with the
WHO grade is consistent with the association between
10q26 abnormalities and the poor prognosis of astrocyto-
mas [7-9,36]. In addition, 2 out 6 GFAP positive oligoden-
droglioma are BCCIP negative, and all 5 cases of
ependymomas are GFAP negative but BCCIP positive.
Discussion
Cytogenetic and LOH analyses have suggested that at least
three distinct regions of the long arm of chromosome 10
are related to brain tumorigenesis: 10q23.3, 10q24–25,
and 10q25.3–26.2. The tumor susceptibility gene located
at 10q23.3 has been identified as the PTEN (phosphatase
and tension homologue detected on chromosome TEN)
or MMAC (mutated in multiple advanced cancers) gene.
PTEN/MMAC protein has two distinct structural domains,
the phosphatase domain and a C2 domain that binds
phospholipid membranes in vitro [37]. PTEN mutations
have been identified in a variety of human cancers [38-
41]. A second tumor susceptibility gene is located at
10q24–25. The c-Myc, Max homologous gene MXI1 is
located in this region [17,42-50].
Lack of BCCIP expression in brain tumors Figure 2
Lack of BCCIP expression in brain tumors. Serial tissue sections were stained for GFAP and BCCIP separately. Both 
GFAP and BCCIP are stained in brown color. Hematoxylin (blue) was used to counter stain the nuclei. Shown are example 
brain tissues stained with antibodies against GFAP and BCCIP (magnification is 40 × 10). Top panel is a representative non-
tumor section. The middle panel is an example section of BCCIP positive tumor, and the bottom panel shows a BCCIP nega-
tive tumor section.BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
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A putative tumor susceptibility gene DMBT1 (Deleted in
Malignant Brain Tumors) has been identified in 10q25.3–
26.2. [51]. DMBT1 is homologous to the scavenger recep-
tor cysteine-rich (SRCR) superfamily of proteins. Since it
is deleted in a large proportion of brain tumors, it has
been suggested as a candidate for the tumor susceptibility
gene in this region. However, expression of DMBT1 in
tumor cells has little effect on tumor cell growth or tumor
associated phenotypes [4,52-54]. This opens the possibil-
ity that additional genes in this region may be relevant to
brain tumorigenesis. Considering that: 1) BCCIP interacts
with BRCA2 and p21, 2) BCCIP plays a role in homolo-
gous recombination, cell cycle regulation, p53 transcrip-
tion activity, and chromosome instability [19-24,26,27],
3) BCCIP expression is absent in a significant portion of
astrocytomas (Figure 2), and 4) the lack of BCCIP expres-
sion is correlated with the aggressiveness of astrocytomas
(Figure 3), we suggest that BCCIP is a strong candidate for
the tumor suppressor gene in the chromosome 10q26
region. However, additional investigation, preferably with
animal knock-out or knock-down models, is needed to
conclude whether BCCIP defects directly cause brain
tumor. It should be pointed out that the 10q26.2 region
has been implicated in many other cancer types. The role
of BCCIP in other cancer types warrants additional inves-
tigations.
Mutation of p53 has been reported in 31% of brain
tumor, but LOH of the 10q region has been reported in
69% of brain tumor [9]. Despite that majority of the brain
tumor harbors wild type p53, brain tumors are well
known for their radiation resistance. We reported that in
the absence of BCCIP, the transactivation activity of wild
type p53 protein is not sustainable [26]. Down-regulation
of BCCIP leads to a resistance to ionizing radiation of
HCT116 cells with wild type p53 [26]. It has been recently
shown that lack of BCCIP in p53 wild type laryngeal can-
cer is associated with poor progress in response to radia-
Frequency of loss of BCCIP protein expression in different  WHO grades of astrocytomas [30] Figure 3
Frequency of loss of BCCIP protein expression in dif-
ferent WHO grades of astrocytomas [30]. Shown is the 
percentage of astrocytomas that are BCCIP negative. The p-
values indicate the statistic values between the indicated 
tumor grade groups.
Table 1: Number of cases analyzed by IHC on tissue array
GFAP (+) GFAP (-)
BCCIP (+) BCCIP (-) Total BCCIP (+) BCCIP (-) Total
Astrocytic tumors
Astrocytoma
(Grade II)
21 5 26
Anaplastic Astrocytoma
(Grade III)
14 12 26 2 1 3
Glioblstoma
(Grade IV)
16 23 39 0 2 2
Total 51 40 91 2 3 5
Oligodendroglioma
Oligodendroglioma
(Grade II)
11 2
Anaplastic Oligodendroglioma
(Grade III)
31 4
Total 4 2 6
Ependymoma 50 5
Total 5 0 5BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
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tion therapy [55]. Here we show that a significant portion
of astrocytomas has down-regulation of BCCIP. It would
be interesting to determine whether the lack of BCCIP
expression plays a role in the radiation resistance for these
brain tumors with wild type p53.
The dependence of p53 function on BCCIP makes an
ideal argument that BCCIP may function as a tumor sup-
pressor, and BCCIP defects are responsible for astrocy-
toma aggression and resistant to radiation therapy.
Because BCCIP has also been shown to be required for
completion of mitosis, and severe knockdown of BCCIP
resulted in growth retardation in other cell types [27], it
remains to be addressed how loss of BCCIP expression
may lead to brain tumor survival. Thus, it is likely that lack
of BCCIP expression needs to be coupled with additional
genetic alterations for tumor cells to be viable and remain
aggressive. If this is true, then identification of these addi-
tional genetic factor(s) enabling BCCIP defective cells to
survive is a critical issue for future studies.
Conclusion
We found that BCCIP expression is down-regulated in a
significant portion of astrocytomas, and the loss of BCCIP
expression is more frequent in the aggressive form of
astrocytomas. These data suggest BCCIP as a potential
marker for brain tumorigenesis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
JL designed and conducted the quantitative PCR analysis,
and drafted a portion of the manuscript. HL conducted
the IHC experiments and drafted a portion of the manu-
script. ZS designed the study, performed data analysis,
and finalized the manuscript, HO provided 1/3 of the
DNA samples and evaluated some of the IHC slides, AM
provided the 2/3 of tumor DNA samples. Both HO and
AM provided inputs on improving an early draft of the
manuscript.
Acknowledgements
This research was supported by National Institute of Health grants 
CA115488.
References
1. Rasheed BK, Fuller GN, Friedman AH, Bigner DD, Bigner SH: Loss
of heterozygosity for 10q loci in human gliomas.  Genes Chro-
mosomes Cancer 1992, 5:75-82.
2. Karlbom AE, James CD, Boethius J, Cavenee WK, Collins VP, Nor-
denskjold M, Larsson C: Loss of heterozygosity in malignant gli-
omas involves at least three distinct regions on chromosome
10.  Hum Genet 1993, 92:169-74.
3. Balesaria S, Brock C, Bower M, Clark J, Nicholson SK, Lewis P, de
Sanctis S, Evans H, Peterson D, Mendoza N, et al.: Loss of chromo-
some 10 is an independent prognostic factor in high-grade
gliomas.  Br J Cancer 1999, 81:1371-7.
4. Steck PA, Lin H, Langford LA, Jasser SA, Koul D, Yung WK, Pershouse
MA: Functional and molecular analyses of 10q deletions in
human gliomas.  Genes Chromosomes Cancer 1999, 24:135-43.
5. Fujisawa H, Reis RM, Nakamura M, Colella S, Yonekawa Y, Kleihues
P, Ohgaki H: Loss of heterozygosity on chromosome 10 is
more extensive in primary (de novo) than in secondary
glioblastomas.  Lab Invest 2000, 80:65-72.
6. Daido S, Takao S, Tamiya T, Ono Y, Terada K, Ito S, Ouchida M, Date
I, Ohmoto T, Shimizu K: Loss of heterozygosity on chromo-
some 10q associated with malignancy and prognosis in astro-
cytic tumors, and discovery of novel loss regions.  Oncol Rep
2004, 12:789-95.
7. Hill C, Hunter SB, Brat DJ: Genetic markers in glioblastoma:
prognostic significance and future therapeutic implications.
Adv Anat Pathol 2003, 10:212-7.
8. Ohgaki H: Genetic pathways to glioblastomas.  Neuropathology
2005, 25:1-7.
9. Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre
PL, Burkhard C, Schuler D, Probst-Hensch NM, Maiorka PC, et al.:
Genetic pathways to glioblastoma: a population-based study.
Cancer Res 2004, 64:6892-9.
10. Merlo A: Genes and pathways driving glioblastomas in
humans and murine disease models.  Neurosurg Rev 2003,
26:145-58.
11. Maier D, Zhang Z, Taylor E, Hamou MF, Gratzl O, Van Meir EG, Scott
RJ, Merlo A: Somatic deletion mapping on chromosome 10
and sequence analysis of PTEN/MMAC1 point to the 10q25–
26 region as the primary target in low-grade and high-grade
gliomas.  Oncogene 1998, 16:3331-5.
12. Ohgaki H, Kleihues P: Population-based studies on incidence,
survival rates, and genetic alterations in astrocytic and oli-
godendroglial gliomas.  J Neuropathol Exp Neurol 2005, 64:479-89.
13. Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL,
Franceschi S, Ohgaki H: Correlation among pathology, geno-
type, and patient outcomes in glioblastoma.  J Neuropathol Exp
Neurol 2006, 65:846-54.
14. Ittmann M: Allelic loss on chromosome 10 in prostate adeno-
carcinoma.  Cancer Res 1996, 56:2143-7.
15. Ittmann MM: Chromosome 10 alterations in prostate adeno-
carcinoma (review).  Oncol Rep 1998, 5:1329-35.
16. Peiffer SL, Herzog TJ, Tribune DJ, Mutch DG, Gersell DJ, Goodfellow
PJ: Allelic loss of sequences from the long arm of chromo-
some 10 and replication errors in endometrial cancers.  Can-
cer Res 1995, 55:1922-6.
17. Petersen S, Wolf G, Bockmuhl U, Gellert K, Dietel M, Petersen I:
Allelic loss on chromosome 10q in human lung cancer: asso-
ciation with tumour progression and metastatic phenotype.
Br J Cancer 1998, 77:270-6.
18. Couzin J: The twists and turns in BRCA's path.  Science 2003,
302:591-3.
19. Meng X, Lu H, Shen Z: BCCIP functions through p53 to regu-
late the expression of p21Waf1/Cip1.  Cell Cycle 2004,
3:1457-62.
20. Liu J, Yuan Y, Huan J, Shen Z: Inhibition of breast and brain can-
cer cell growth by BCCIPalpha, an evolutionarily conserved
nuclear protein that interacts with BRCA2.  Oncogene 2001,
20:336-45.
21. Ono T, Kitaura H, Ugai H, Murata T, Yokoyama KK, Iguchi-Ariga SM,
Ariga H: TOK-1, a novel p21Cip1-binding protein that coop-
eratively enhances p21-dependent inhibitory activity toward
CDK2 kinase.  J Biol Chem 2000, 275:31145-54.
22. Lu H, Guo X, Meng X, Liu J, Allen C, Wray J, Nickoloff JA, Shen Z:
The BRCA2-interacting protein BCCIP functions in RAD51
and BRCA2 focus formation and homologous recombina-
tional repair.  Mol Cell Biol 2005, 25:1949-57.
23. Meng X, Liu J, Shen Z: Inhibition of G1 to S cell cycle progres-
sion by BCCIP beta.  Cell Cycle 2004, 3:343-8.
24. Lu H, Yue J, Meng X, Nickoloff JA, Shen Z: BCCIP regulates
homologous recombination by distinct domains and sup-
presses spontaneous DNA damage.  Nucleic Acids Res 2007,
35:7160-7170.
25. Wray J, Liu J, Nickoloff JA, Shen Z: Distinct RAD51 associations
with RAD52 and BCCIP in response to DNA damage and
replication stress.  Cancer Research 2008, 68:2699-2707.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2009, 9:268 http://www.biomedcentral.com/1471-2407/9/268
Page 8 of 8
(page number not for citation purposes)
26. Meng X, Yue J, Liu Z, Shen Z: Abrogation of the transactivation
activity of p53 by BCCIP down-regulation.  J Biol Chem 2007,
282:1570-6.
27. Meng X, Fan J, Shen Z: Roles of BCCIP in chromosome stability
and cytokinesis.  Oncogene 2007, 26:6253-60.
28. Roversi G, Pfundt R, Moroni RF, Magnani I, van Reijmersdal S, Pollo
B, Straatman H, Larizza L, Schoenmakers EF: Identification of novel
genomic markers related to progression to glioblastoma
through genomic profiling of 25 primary glioma cell lines.
Oncogene 2006, 25:1571-83.
29. Reifenberger G, Collins VP: Pathology and molecular genetics of
astrocytic gliomas.  J Mol Med 2004, 82:656-70.
30. Kleihues P, Louis DN, Scheithauer BW, Rorke LB, Reifenberger G,
Burger PC, Cavenee WK: The WHO classification of tumors of
the nervous system.  J Neuropathol Exp Neurol 2002, 61:215-25. dis-
cussion 226–9.
31. Maier D, Comparone D, Taylor E, Zhang Z, Gratzl O, Van Meir EG,
Scott RJ, Merlo A: New deletion in low-grade oligodendrogli-
oma at the glioblastoma suppressor locus on chromosome
10q25–26.  Oncogene 1997, 15:997-1000.
32. Watanabe T, Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H: Pro-
moter hypermethylation and homozygous deletion of the
p14ARF and p16INK4a genes in oligodendrogliomas.  Acta
Neuropathol 2001, 101:185-9.
33. Meng X, Liu J, Shen Z: Genomic structure of the human BCCIP
gene and its expression in cancer.  Gene 2003, 302:139-46.
34. Shih AH, Holland EC: Developmental neurobiology and the ori-
gin of brain tumors.  J Neurooncol 2004, 70:125-36.
35. Eng LF, Ghirnikar RS: GFAP and astrogliosis.  Brain Pathol 1994,
4:229-37.
36. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H:
Acquisition of the glioblastoma phenotype during astrocy-
toma progression is associated with loss of heterozygosity
on 10q25-qter.  Am J Pathol 1999, 155:387-94.
37. Lee JO, Yang H, Georgescu MM, Di Cristofano A, Maehama T, Shi Y,
Dixon JE, Pandolfi P, Pavletich NP: Crystal structure of the PTEN
tumor suppressor: implications for its phosphoinositide
phosphatase activity and membrane association.  Cell 1999,
99:323-34.
38. Rossi DJ, Weissman IL: Pten, tumorigenesis, and stem cell self-
renewal.  Cell 2006, 125:229-31.
39. Chow LM, Baker SJ: PTEN function in normal and neoplastic
growth.  Cancer Lett 2006, 241:184-96.
40. Stiles B, Groszer M, Wang S, Jiao J, Wu H: PTENless means more.
Dev Biol 2004, 273:175-84.
41. Leslie NR, Downes CP: PTEN function: how normal cells con-
trol it and tumour cells lose it.  Biochem J 2004, 382:1-11.
42. Scott DK, Straughton D, Cole M, Bailey S, Ellison DW, Clifford SC:
Identification and analysis of tumor suppressor loci at chro-
mosome 10q23.3–10q25.3 in medulloblastoma.  Cell Cycle
2006, 5:2381-9.
43. Ariyanayagam-Baksh SM, Baksh FK, Swalsky PA, Finkelstein SD: Loss
of heterozygosity in the MXI1 gene is a frequent occurrence
in melanoma.  Mod Pathol 2003, 16:992-5.
44. Herbst RA, Podewski EK, Mommert S, Kapp A, Weiss J: PTEN and
MXI1 allelic loss on chromosome 10q is rare in melanoma in
vivo.  Arch Dermatol Res 1999, 291:567-9.
45. Prochownik EV, Eagle Grove L, Deubler D, Zhu XL, Stephenson RA,
Rohr LR, Yin X, Brothman AR: Commonly occurring loss and
mutation of the MXI1 gene in prostate cancer.  Genes Chromo-
somes Cancer 1998, 22:295-304.
46. Kuczyk MA, Serth J, Bokemeyer C, Schwede J, Herrmann R, Machtens
S, Grunewald V, Hofner K, Jonas U: The MXI1 tumor suppressor
gene is not mutated in primary prostate cancer.  Oncol Rep
1998, 5:213-6.
47. Wechsler DS, Shelly CA, Petroff CA, Dang CV: MXI1, a putative
tumor suppressor gene, suppresses growth of human gliob-
lastoma cells.  Cancer Res 1997, 57:4905-12.
48. Kim SK, Ro JY, Kemp BL, Lee JS, Kwon TJ, Hong WK, Mao L: Iden-
tification of two distinct tumor-suppressor loci on the long
arm of chromosome 10 in small cell lung cancer.  Oncogene
1998, 17:1749-53.
49. Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA,
Saini K, Libertino JA, Summerhayes IC: Molecular analysis of
PTEN and MXI1 in primary bladder carcinoma.  Int J Cancer
2000, 88:620-5.
50. Delnatte C, Sanlaville D, Mougenot JF, Vermeesch JR, Houdayer C,
Blois MC, Genevieve D, Goulet O, Fryns JP, Jaubert F, et al.: MXI1, a
putative tumor suppressor gene, suppresses growth of
human glioblastoma cells.  Am J Hum Genet 2006, 78:1066-74.
51. Mollenhauer J, Wiemann S, Scheurlen W, Korn B, Hayashi Y, Wilgen-
bus KK, von Deimling A, Poustka A: DMBT1, a new member of
the SRCR superfamily, on chromosome 10q25.3–26.1 is
deleted in malignant brain tumours.  Nat Genet 1997, 17:32-9.
52. Sasaki H, Betensky RA, Cairncross JG, Louis DN: DMBT1 polymor-
phisms: relationship to malignant glioma tumorigenesis.
Cancer Res 2002, 62:1790-6.
53. Sanson M, Leuraud P, Aguirre-Cruz L, He J, Marie Y, Cartalat-Carel S,
Mokhtari K, Duffau H, Delattre JY, Hoang-Xuan K: Analysis of loss
of chromosome 10q, DMBT1 homozygous deletions, and
PTEN mutations in oligodendrogliomas.  J Neurosurg 2002,
97:1397-401.
54. Pang JC, Dong Z, Zhang R, Liu Y, Zhou LF, Chan BW, Poon WS, Ng
HK: Mutation analysis of DMBT1 in glioblastoma, medullob-
lastoma and oligodendroglial tumors.  Int J Cancer 2003,
105:76-81.
55. Rewari A, Lu H, Parikh R, Yang Q, Shen Z, Haffty BG: BCCIP as a
prognostic marker for radiotherapy of laryngeal cancer.
Radiother Oncol 2009, 90:183-8.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/9/268/pre
pub